CLAIMS

What is claimed is:

Claim 1. A method for treating a patient suffering from a cancerous disease comprising:

administering to said patient anti-cancer antibodies or fragments thereof produced in accordance with a method for the production of individually customized anti-cancer antibodies which are useful in treating a cancerous disease, said antibodies including a subset of antibodies or fragments thereof characterized as being cytotoxic against cells of a cancerous tissue, said subset being essentially benign to non-cancerous cells;

wherein one or more antibodies or fragments thereof selected from said subset are placed in admixture with a pharmaceutically acceptable adjuvant and are administered in an amount effective to mediate treatment of said cancerous disease.

Claim 2. The method for treating a patient suffering from a cancerous disease in accordance with claim 1, wherein said one or more antibodies or fragments thereof selected from said subset are humanized.

Claim 3. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 comprising:

conjugating said subset of antibodies or fragments thereof with a member selected from the group consisting of toxins, enzymes, radioactive compounds, and hematogenous cells; and

administering conjugated antibodies or fragments thereof to said patient;

wherein said conjugated antibodies are placed in admixture with a pharmaceutically acceptable adjuvant and are administered in an amount effective to mediate treatment of said cancerous disease.

Claim 4. The method of claim 3, wherein said one or more antibodies or fragments thereof selected from said subset are humanized.

Claim 5. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibodies or fragments thereof is mediated through antibody dependent cellular toxicity.

Claim 6. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibodies or fragments thereof is mediated through complement dependent cellular toxicity.

Claim 7. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibodies or fragments thereof is mediated through catalyzing of the hydrolysis of cellular chemical bonds.

Claim 8. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibodies or fragments thereof is mediated through producing an immune response against putative cancer antigens residing on tumor cells.

Claim 9. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibodies or fragments thereof is mediated through targeting of cell membrane proteins to interfere with their function.

Claim 10. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the cytotoxicity of said antibodies or fragments thereof is mediated through production of a conformational change in

a cellular protein effective to produce a signal to initiate cell-killing.

Claim 11. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

said method of production utilizes a tissue sample containing cancerous and non-cancerous cells obtained from a particular individual.

Claim 12. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the antibodies or fragments thereof are selected from the group consisting of a 3BD-3, a 3BD-6, a 3BD-8, a 3BD-9, a 3BD-15, a 3BD-25, a 3BD-26 and a 3BD-27 monoclonal antibody or combinations thereof.

Claim 13. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the antibodies or fragment thereof are produced by one or more hybridoma cell lines having an ATCC Accession Number selected from the group consisting of ( ).

Claim 14. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the antibodies or fragments thereof are selected from the group consisting of a 1LN-1, a 1LN-12, a 1LN-14, a 2LN-

21, a 2LN-28, a 2LN-29, a 2LN-31, a 2LN-33, a 2LN-34 and a 2LN-35 monoclonal antibody or combinations thereof.

Claim 15. The method for treating a patient suffering from a cancerous disease in accordance with claim 1 wherein:

the antibodies or fragments thereof are produced by one or more hybridoma cell lines having an ATCC Accession Number selected from the group consisting of ( ).